Economic evaluation of pazopanib as first-line treatment of metastatic renal cell carcinoma in Greece

Date

09 Oct 2016

Session

Poster display

Presenters

Argyro Solakidi

Citation

Annals of Oncology (2016) 27 (6): 351-358. 10.1093/annonc/mdw377

Authors

A. Solakidi1, G. Kourlaba1, L. Kontovinis2, E. Bournakis3, A. Boutis4, K. Koutsoukos5, I. Syrios6, A. Tzovaras7, M. Chatzikou8, C. Michailidi9, N. Maniadakis10

Author affiliations

  • 1 Health Economics, EVROSTON LP, 11528 - Athens/GR
  • 2 Medical Oncology, Oncomedicare, Thessaloniki/GR
  • 3 Medical Oncology, Areteion Hospital, University of Athens, Athens/GR
  • 4 1st Department Of Clinical Oncology/chemotherapy, Theagenion Cancer Hospital, 540 07 - Thessaloniki/GR
  • 5 Oncology Unit/ Department Of Clinical Therapeutics, Alexandra Hospital, 115 28 - Athens/GR
  • 6 Medical Oncology, Hygeia Hospital, Athens/GR
  • 7 Medical Oncology, Hippokration General Hospital, Athens/GR
  • 8 Health Economics, Novartis Hellas, Athens/GR
  • 9 Medical, Novartis Hellas, Athens/GR
  • 10 Health Services Organization And Management, National School of Public Health, Athens/GR
More

Resources

Background

The NCCN Kidney Cancer Panel lists pazopanib and sunitinib as category 1 options for first-line treatment for stage IV renal cell carcinoma (RCC) patient. The aim of this study was to evaluate the cost-effectiveness of pazopanib vs sunitinib as first-line treatment of metastatic RCC (mRCC) from a Greek third-party payer's perspective.

Methods

A 3-state partitioned survival model was used. Estimates of progression free survival (PFS) and overall survival (OS) were from the COMPARZ trial. Utility values were based on adverse events in COMPARZ and EQ-5D data from the VEG105192 trial. Cost inputs included drug acquisition and other treatment related costs including physician visits and lab and radiology tests. Resource use data were collected by DELPHI method from an expert panel of clinicians from private and public hospitals in Greece. A 5-year time horizon was used consistent with the maximum duration of follow-up in the final analysis of OS in COMPARZ. The incremental cost-effectiveness ratio (ICER) was calculated. A threshold of €35,000 per QALY gained was used, per WHO Guidelines. Deterministic and probabilistic sensitivity analyses (DSA and PSA) were conducted.

Results

In the base case, pazopanib was less costly and more effective (“dominant”) compared with sunitinib, with €3,676 lower lifetime costs per patient and 0.058 greater discounted QALYs (€25,464 vs €29,140 and 1.617 vs 1.558). DSA and PSA suggest these results are robust. In DSA, pazopanib was dominant for different assumptions regarding PFS and utilities (Table). In 66% of PSA simulations, pazopanib was projected to yield more QALYs and lower costs vs sunitinb. The probability that pazopanib is cost-effective vs sunitinib was estimated to be 90% given the ICER threshold.

Scenario Incremental Costs Incremental QALYs ICER
Base case (IRC PFS) -€3,676 0.058 Dominant
Investigator-assessed PFS -€2,804 0.059 Dominant

Conclusions

Pazopanib is likely to be dominant compared with sunitinib as first-line treatment of mRCC in the Greek healthcare setting.

Clinical trial identification

Legal entity responsible for the study

Dr. Georgia Kourlaba

Funding

Novartis Hellas

Disclosure

A. Solakidi, G. Kourlaba: EVROSTON LP received funding from Novartis Hellas for this study M. Chatzikou: Novartis employee. However, the study sponsor had no influence on the study design, data collection or writing of the abstract. C. Michailidi: Novartis employee. However, the study sponsor had no influence on the study design, data collection or writing of the abstract. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings